News

New Alzheimer’s target
Enlarge image

ScienceBelgium

New Alzheimer’s target

04.12.2012 - Scientists from VIB and KU Leuven have discovered a new target that could lay the foundations for a new approach to treat Alzheimer’s disease.

The research team, headed by Bart de Strooper from VIB, found that β-arrestin 2 blocks the plaque-form enzyme γ-secretase through interaction with the G protein–coupled receptors GPR3 and β2 -adrenergic receptor (Nature Medicine). Furthermore, they demonstrated that β-arrestin 2 was overexpressed in two independent cohorts of Alzheimer patients. Overexpression of the protein led to an increase in sticky amyloid-β (Aβ) peptides, called Aβ40 and Aβ42, which form the amyloid plaques that are associated with neurodegeneration. In contrast, genetic silencing of Arrb2, which encodes β-arrestin 2, reduced generation of Aβ in cell cultures and in knock-out mice for the Alzheimer regulator. The effect was mediated by direct binding to the Aph-1a subunit of the γ-secretase complex, which enzymatically generates the sticky Aβ peptides. Thus the scientists believe that inhibitors of β-arrestin 2 could block the generation of Aβ40 and Aβ42, in early stages of Alzheimer’s when no symptoms have yet emerged.

Currently there is no cure for the neurodegenerative disease. Many candidate drugs that target the γ-secretase complex fail because they also target proteins essential to life. The discovery from Leuven could form a target for a treatment against Alzheimer’s disease with fewer side effects and that suppresses the very first symptoms of the disease. β-arrestin 2 inhibition could be beneficial in prevention of the adverse side effects currently associated with γ-secretase inhibition. This study thus provides a previously unexplored avenue for the development of a treatment that can act at a very early stage of Alzheimer’s disease.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2012-04/new-alzheimers-target.html

LicensingSwitzerland

30.08.2016 Swiss biopharma company Ferring has acquired the exclusive development and commercialisation rights to Seikagaku’s Phase III chemonucleolytic leg pain treatment for €85m.

Clinical TrialsFrance

26.08.2016 Adocia said it would discontinue its diabetic foot ulcer programme after its lead product BioChaperone PDGF disappointed in Phase III. The French company will turn the focus on its earlier-stage products.

M&AUKSweden

24.08.2016 Pharma major Pfizer is putting the cherry on top of its multi-billion-dollar takeover of Medivation with the acquisition of AstraZeneca’s antibiotics for a cool US$1.5bn. With the divestment, AZ aims to further sharpen its focus.

FinancingUK

23.08.2016 Cambridge University-allied investor Cambridge Innovation Capital has raised £75m (€87m) to reinvest in technology and healthcare companies. Among the backers were Woodford Investment and Winton Ventures.

R&DDenmark

19.08.2016 Together with partner Johnson & Johnson, Danish biotech Genmab is now one step closer to FDA approval with its combination treatment for multiple myeloma after its submission of a supplemental Biologics License Application. In July, Genmab was granted a Breakthrough Therapy Designation (BTD) for its blood cancer therapy.

ResearchUKEU

17.08.2016 Philip Hammond, the UK’S chancellor has announced the government will guarantee funding for EU-backed "structural and investment fund" projects whose timelines extend beyond the UK’s departure from the EU, provided the projects are signed prior to this year's Autumn Statement on the UK budget. The decision ensures continued funding for farmers, companies and institutions involved in the EU’s Horizon 2020 project. The move could cost the UK government up to £6bn (€6.9bn).

Stock marketsGermany

15.08.2016 Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC).

LicensingDenmark

11.08.2016 Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Clinical developmentHungaryIreland

09.08.2016 Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

ImmunotherapySpain

08.08.2016 Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • ARGEN-X (B)14.20 EUR5.19%
  • MAGFORCE (D)4.71 EUR4.43%
  • DIAMYD MEDICAL -B- (S)7.20 SEK4.35%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-6.82%
  • PHOTOCURE (N)41.00 NOK-6.61%
  • SAREUM HOLDINGS (UK)0.74 GBP-5.13%

TOP

  • NORDIC NANOVECTOR (N)34.50 NOK40.8%
  • KARO BIO (S)43.10 SEK30.6%
  • MOLMED (I)0.42 EUR27.3%

FLOP

  • BIONOR PHARMA (N)0.41 NOK-28.1%
  • GW PHARMACEUTICALS (UK)514.61 GBP-13.6%
  • WILEX (D)1.46 EUR-13.6%

TOP

  • NICOX (F)10.29 EUR430.4%
  • SAREUM HOLDINGS (UK)0.74 GBP236.4%
  • GENMAB (DK)1085.00 DKK81.6%

FLOP

  • BB BIOTECH (D)44.30 EUR-82.9%
  • EVOCUTIS (UK)0.04 GBP-77.8%
  • CIRCASSIA LIMITED (L)92.00 GBP-73.1%

No liability assumed, Date: 30.08.2016